Pediatric Melanoma and Atypical Melanocytic Neoplasms

Kumar, Radhika; Messina, Jane L.; Reed, Damon R.; Sondak, Vernon K.

doi:10.1007/978-3-319-78310-9_13

Cited by 4 publications

(7 citation statements)

References 144 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2,5,12 However, we observed largely stable or decreasing rates year-after-year starting in 2006. Two recent studies have TA B L E 2…”

mentioning

confidence: 54%

“…5,25 This may be due to fewer comorbidities and a greater frequency of benign lesions, such as Spitz nevi, being erroneously upstaged to melanoma. 1,6,11,12,17,26 Given the rarity of pediatric melanoma, a major strength of NCDB is that it captures 70% of American cancer diagnoses. Major limitations are that NCDB only provides all-cause mortality data, does not report genetic mutations or coexisting medical conditions, and does not document a Fitzpatrick skin type.…”

Section: Discussionmentioning

confidence: 99%

“…However, melanoma in this age group has been observed in previous studies. 1,2,12,15,17,18 Compared by race/ethnicity, most tumors occurred in White patients, followed by Hispanics. The disproportionate burden of melanoma in White patients is well-known and documented in previous studies.…”

Section: Discussionmentioning

confidence: 99%

“…

…”

mentioning

confidence: 99%

See 3 more Smart Citations

THE demographics and trends in pediatric melanoma in the United States: An analysis of the National Cancer Database

Yousif

Boull

Gerami

et al. 2021

Pediatric Dermatology

View full text Add to dashboard Cite

Melanoma is uncommon in the pediatric population: it accounts for 1%-3% of all pediatric malignancies and approximately 1%-4% of all melanomas occur in pediatric patients. 1,2 Several recent studies have detected an increase in the incidence of pediatric melanomas over the past 3 decades at a rate of 2%-3% per year. [1][2][3][4] The current diagnosis and treatment of pediatric melanoma are often based on the experiences of adults. 1,5 However, pediatric melanomas face several diagnostic challenges. Unlike adult melanomas, pediatric tumors often present as an amelanotic papule with regular borders and uniform coloration. 6 Pediatric melanomas often have unusual histologic patterns, with workup including fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH),

show abstract

“…1,2,5,12 However, we observed largely stable or decreasing rates year-after-year starting in 2006. Two recent studies have TA B L E 2…”

mentioning

confidence: 54%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…

…”

mentioning

confidence: 99%

See 2 more Smart Citations

THE demographics and trends in pediatric melanoma in the United States: An analysis of the National Cancer Database

Yousif

Boull

Gerami

et al. 2021

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

“…Favor benign included those with focal proliferation but limited scope, while favor malignant include Spitz-like neoplasms with high dermal cellularity, deep dermal extension, high mitotic rate deep in the dermis, and asymmetry and necrosis. 19 Lesion severity was assessed by examining Breslow thickness, presence of ulceration, mitotic count, and Clark level of invasion. Measured outcomes include the use of SLNB, follow-up CLND, primary lesion recurrence, and overall, regional, and distant disease-free survival.…”

Section: Methodsmentioning

confidence: 99%

Sentinel Node Biopsy in Young Patients with Atypical Melanocytic Tumors of the Head and Neck

et al. 2019

View full text Add to dashboard Cite

Objective To examine the diagnostic value of the sentinel lymph node biopsy in pediatric through young adult head and neck melanocytic tumors of unknown malignant potential. Study Design Retrospective case series. Setting Single academic institution. Subjects and Methods Demographics, histology, and outcomes were examined in 14 patients aged 4 to 24 years with head and neck melanocytic tumors of unknown malignant potential. Information on age at diagnosis, primary lesion characteristics, and sentinel lymph node biopsy were compared. Results Of 14 patients meeting criteria for head and neck melanocytic tumors of unknown malignant potential, 8 patients underwent sentinel lymph node biopsy (57%). Of those, 4 biopsies (50%) had positive sentinel nodes. All patients undergoing sentinel lymph node biopsy had primary lesions greater than 1 mm depth or mitotic rate of at least 1 mitosis per mm 2 . No patients had recurrence of their primary lesion at time of follow-up. Conclusion Our data show a high rate of node-positive sentinel lymph node biopsy for pediatric and young adult head and neck patients with melanocytic tumors of unknown malignant potential, supporting the value of sentinel lymph node biopsy in this population.

show abstract

Higher than reported adolescent and young adult clinical trial enrollment during the “Golden Age” of melanoma clinical trials

et al. 2018

View full text Add to dashboard Cite

Clinical trial enrollments in adolescents and young adults (AYA) with cancer have historically been lower than those in pediatric and older adult populations. We sought to examine therapeutic trial enrollment rates at our cancer center. We performed a retrospective evaluation of AYA patients treated before and after the first checkpoint inhibitor trial opened at our cancer center in 2007. We examined gender, stage at presentation and insurance status in terms of trial enrollment. We compared the trial participation rate of AYA patients with that of older adults. In this adult facility, 12.7% (1,831) of total patients were between age 15 and 39. Overall therapeutic clinical trial rate was 17.6% which increased to 19.8% since 2007. Both nodal disease or metastatic disease at presentation was associated with increasing odds of trial enrollment (OR = 5.36 and P < 0.001 for nodal disease and OR = 7.96 and P < 0.001 for metastatic disease). There was a nonstatistically significant trend toward improved 3‐year overall survival in the AYA patients with advanced presentation that enrolled on clinical trials compared with those not enrolled on trials since 2007. AYA clinical trial enrollment at a comprehensive care center melanoma program was higher than reported in the literature overall for AYA patients. This 1,831 patient cohort may provide a foundation for more detailed investigation toward quantifying the effects of clinical trial enrollment in terms of age‐specific benefits and toxicities for AYA patients with malignancies that have their peak incidence in older adults.

show abstract

Pediatric Melanoma and Atypical Melanocytic Neoplasms

Cited by 4 publications

References 144 publications

THE demographics and trends in pediatric melanoma in the United States: An analysis of the National Cancer Database

THE demographics and trends in pediatric melanoma in the United States: An analysis of the National Cancer Database

Sentinel Node Biopsy in Young Patients with Atypical Melanocytic Tumors of the Head and Neck

Higher than reported adolescent and young adult clinical trial enrollment during the “Golden Age” of melanoma clinical trials

Contact Info

Product

Resources

About